Cellectis S.A.
CLLS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CLLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLLS
Cellectis S.A. is a clinical-stage biopharmaceutical company developing allogeneic CAR T-cell immunotherapies using gene-editing technology, with lead product candidates in clinical trials and a history of net losses since inception.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials · 1 catalyst for Cellectis S.A..
Cellectis S.A. is a clinical-stage biopharmaceutical company developing allogeneic CAR T-cell immunotherapies using gene-editing technology, with lead product candidates in clinical trials and a history of net losses since inception.
- Cellectis is a clinical-stage biopharmaceutical company focused on CAR T-cell immunotherapy product candidates [sec · filed 2026-03-20].
- The company has incurred net losses in every period since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future [sec · filed 2026-03-20].
- As of 2025-12-31, Cellectis reported cash & equivalents of $61.5M, shareholders' equity of $125.9M, and total debt of $103.1M [sec].
- The company is sponsoring three clinical studies and advancing pre-clinical testing for additional product candidates [sec · filed 2026-03-20].
- Cellectis' business is highly dependent on the success of its lead product candidates, and there is no assurance of regulatory approval or successful commercialization [sec · filed 2026-03-20].
What works
- Cellectis is advancing multiple clinical studies and preparing regulatory filings for new studies, indicating ongoing pipeline progress [sec · filed 2026-03-20].
- The company has in-house manufacturing facilities to support its CAR T-cell product development [sec · filed 2026-03-20].
What to weigh
- Cellectis has incurred net losses in every period since inception and expects to continue incurring substantial net losses for the foreseeable future [sec · filed 2026-03-20].
- The company may need to raise additional funding, which may not be available on acceptable terms or at all, and its ability to raise share capital is limited by French corporate law [sec · filed 2026-03-20].
- Clinical trials for its product candidates are time-consuming, expensive, and subject to high risk of failure, with no guarantee of success [sec · filed 2026-03-20].
- The company faces competition from entities with significantly greater resources [sec · filed 2026-03-20].
From the filings
Quoted directly from source documents.
Cellectis has incurred net losses since inception and expects future losses.
“As a clinical-stage biopharmaceutical company, we have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.”
SEC filings · March 20, 2026
The company is sponsoring three clinical studies and advancing pre-clinical testing.
“We are currently sponsoring three clinical studies, preparing regulatory filings to potentially commence new clinical studies and/or to add additional investigational sites for ongoing studies, advancing pre-clinical testing for additional product candidates, and conducting manufacturing at our in-house manufacturing facilities.”
SEC filings · March 20, 2026
Cellectis' business is highly dependent on the success of its lead product candidates.
“Our business is highly dependent on the success of our lead product candidates, and we cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, these product candidates.”
SEC filings · March 20, 2026
The company may need to raise additional funding, with limitations under French law.
“We may need to raise additional funding, which may not be available on acceptable terms or at all, and our ability to raise additional share capital is limited by French corporate law.”
SEC filings · March 20, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · lasme-cel — Phase 2 Readout: lasme-cel — Topline data from the Phase 2 study of lasme-cel is expected, which will be a key indicator of the product candidate's efficacy and safety.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Clinical trials are long, expensive, and unpredictable; failure can occur at any stage, and positive interim results do not guarantee final success [sec · filed 2026-03-20].
- Need for additional capital — The company may need to raise additional funding, which may not be available on acceptable terms or at all, with limitations under French corporate law [sec · filed 2026-03-20].
- Regulatory approval uncertainty — It will be several years, if ever, before regulatory approval and commercialization of a product candidate is achieved [sec · filed 2026-03-20].
- Dependence on lead candidates — The business is highly dependent on the success of lead product candidates, with no assurance of approval or commercialization [sec · filed 2026-03-20].
What to watch
- Phase 2 topline data for lasme-cel expected around 2026-12-31 [catalyst].
- Progress of ongoing clinical studies and any regulatory filings for new trials [sec · filed 2026-03-20].
- Ability to secure additional financing given cash position of $61.5M as of 2025-12-31 [sec].
- Any safety signals or clinical holds that could impact development timelines [sec · filed 2026-03-20].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Cellectis S.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cellectis S.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 3.28
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$3.6M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 341,523 | $1.1M |
| nomura asset management international inc. | 226,875 | $719K |
| eversource wealth advisors, llc | 5,092 | $525K |
| morgan stanley | 86,776 | $275K |
| susquehanna international group, llp | 65,942 | $209K |
| citadel advisors llc | 44,315 | $140K |
| marshall wace, llp | 41,112 | $130K |
| bnp paribas financial markets | 41,000 | $130K |
| ubs group ag | 29,774 | $94K |
| delaney dennis r | 24,000 | $76K |
Showing top 10 of 29 institutional holders of Cellectis S.A.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 9.7
- Shares short
- 364,178
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLLS short interestFrequently asked questions
What is the AI investment thesis for Cellectis S.A.?
Cellectis S.A. is a clinical-stage biopharmaceutical company developing allogeneic CAR T-cell immunotherapies using gene-editing technology, with lead product candidates in clinical trials and a history of net losses since inception.
What is Cellectis S.A.'s next catalyst?
Cellectis S.A.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: lasme-cel" — expected December 31, 2026.
Who is the CEO of Cellectis S.A.?
Dr. Andre Choulika Ph.D. is the chief executive officer of Cellectis S.A. (CLLS).
Where is Cellectis S.A. headquartered?
Cellectis S.A. (CLLS) is headquartered in Paris, France.
What therapeutic areas does Cellectis S.A. focus on?
Cellectis S.A. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.